Skip to main content
Premium Trial:

Request an Annual Quote

Boost Biomes Closes $2.1M in Seed Funding

NEW YORK (GenomeWeb) – Boost Biomes, a startup focused on identifying commercially viable microbial products, announced today its launch with a $2.1 million seed funding round.

San Francisco-based Boost Biomes will use the funds to develop microbiome-based products with an initial focus in agriculture. The firm plans to use its first two products to improve crop yield in the field and reduce spoilage after harvest. Boost Biome's products are currently being evaluated in commercially relevant trials.

The company is a graduate of the Illumina Accelerator, and its platform uses high-throughput next-generation sequencing, selective enrichment, and advanced informatics to identify microbes with important commercial roles. The technology leverages decades of research by University of California, Berkeley professor Adam Arkin on the use of DNA sequencing to understand microbial ecology.

The funding round is led by Nimble Ventures and Viking Global Investors, and includes other participants such as Tencent.

"Our goal is to demonstrate that our approach can sift diversity more efficiently, and arrive at solutions that are more effective than traditional approaches," Boost Biomes cofounder Rob McBride said in a statement.

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.